Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Cue Biopharma Inc (CUE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$18.01-9.22%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CUE yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve clinical milestones for CUE-221 and CUE-401 | Cue Biopharma is working on important clinical goals for CUE-221 and CUE-401. | Improving | Failure to advance clinical milestones for CUE-221 and CUE-401 by FY26 | CUE-221 Phase 2 primary endpoint met (qualitative) Positive Phase 2 topline results for CUE-221 in CSU announced Sept 2026. No recent CUE-401 updates. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not a proven compounder: the business is loss-making and recent performance is weak. The thesis is on watch, with management delivering some clinical and licensing milestones but facing volatile execution and high risk.
The valuation evidence is mixed: one measure points to CUE being cheap versus peers, while another shows a 34% premium, and model confidence is low. Expectations appear close to the evidence, with a small negative gap; the snapshot reports no major fragility signals.
Near term, revenue has risen with collaboration milestones, and management remains on track for the CUE-221 data readout and CUE-401 trial initiation. The company has raised funds through private placements, but cash declined after spending, while weak performance, a litigation filing, and a CFO transition add uncertainty.
Over the next few quarters, the thesis depends on clinical milestones arriving on schedule and collaboration activity continuing to support revenue. A guidance cut or further weakening in jobs data would add pressure; continued strength from healthcare bellwethers could support the sector backdrop.
Over a 1 to 3 year horizon, CUE remains a high-risk, milestone-dependent long-term thesis with some execution progress but limited evidence of durable financial strength. The main tests are clinical delivery, funding needs, and whether recent weakness improves. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| It has a license deal with Ascendant Health Sciences. |
| Intact |
| License agreement with Ascendant Health Sciences fails or stalls by FY26 |
Qualitative: Phase 2 primary endpoint met vs FY26 target Positive Phase 2 topline results for CUE-221 in CSU announced Sept 2026, validating license agreement execution progress. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stability in management and board leadership | A primary condition in Cue Biopharma Inc's published investment case. The stated target is No further major board resignations or CEO changes through 2026. | Under Pressure | Additional major board resignations or CEO departures in 2026 | 4 board resignations vs 0 target News reports four directors resigned from the board in June 2026, violating the stability target. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Progress in strategic partnership with Boehringer Ingelheim | The company also has a partnership with Boehringer Ingelheim. | Intact | No progress in compound selection or lead optimization by FY26 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-9.45 → $-7.44 · observed estimates
$0.00B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-07-25 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-07-26 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-07-27 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-07-28 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-07-29 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-07-30 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-07-31 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-01 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-02 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-03 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-04 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-05 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-06 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-07 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-08 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-09 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-10 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-11 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-12 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-13 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-14 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-15 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-16 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-17 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-18 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-19 | $-9.45 | $1,000,000 | 1 / 1 |
| 2026-08-20 | $-8.49 | $5,000,000 | 1 / 1 |
| 2026-08-21 | $-8.49 | $5,000,000 | 1 / 1 |
| 2026-08-22 | $-8.49 | $5,000,000 | 1 / 1 |
| 2026-08-23 | $-8.49 | $5,000,000 | 1 / 1 |
| 2026-08-24 | $-8.49 | $5,000,000 | 1 / 1 |
| 2026-08-25 | $-8.49 | $5,000,000 | 1 / 1 |
| 2026-08-26 | $-8.49 | $5,000,000 | 1 / 1 |
| 2026-08-27 | $-8.49 | $5,000,000 | 1 / 1 |
| 2026-08-28 | $-8.49 | $5,000,000 | 1 / 1 |
| 2026-08-29 | $-6.83 | $10,281,500 | 1 / 1 |
| 2026-08-30 | $-6.83 | $10,281,500 | 1 / 1 |
| 2026-08-31 | $-6.83 | $10,281,500 | 2 / 1 |
| 2026-09-01 | $-6.83 | $10,281,500 | 2 / 1 |
| 2026-09-02 | $-6.83 | $10,281,500 | 2 / 1 |
| 2026-09-03 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-04 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-05 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-06 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-07 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-08 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-09 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-10 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-11 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-12 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-13 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-14 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-15 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-16 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-17 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-18 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-19 | $-6.83 | $10,281,500 | 2 / 2 |
| 2026-09-20 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-09-21 | $-7.44 | $8,654,333 | 3 / 3 |
| 2026-09-22 | $-7.44 | $8,654,333 | 3 / 3 |
| 2026-09-23 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-09-24 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-09-25 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-09-26 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-09-27 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-09-28 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-09-29 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-09-30 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-01 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-02 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-03 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-04 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-05 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-06 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-07 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-08 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-09 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-10 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-11 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-12 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-13 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-14 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-15 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-16 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-17 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-18 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-19 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-20 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-21 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-22 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-23 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-24 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-25 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-26 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-27 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-28 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-29 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-30 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-10-31 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-11-01 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-11-02 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-11-03 | $-7.44 | $8,654,333 | 2 / 2 |
| 2026-11-04 | $-7.44 | $8,654,333 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.